P-344 The role of postoperative prognostic nutritional index as a prognostic factor and its association to systemic inflammatory response markers in stage III colon cancer

Costa, Igor Brasil; Reis, Jorge; Costa, Max; Valente, Andreia; Fernandes, C.; Tavares, N.; Rey, C.; Sarmento, C.

doi:10.1016/j.annonc.2020.04.426

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, specific grading of the reported deficits is missing [27]. In the analyzed abstracts, both PNI [9,14] and PG-SGA found application [12,13].…”

Section: Discussionmentioning

confidence: 99%

“…In the multivariate analysis, PNI ≤ 51.70 maintained a negative impact only on DFS (HR 1.457; CI 95% 1.215-1.749; p < 0.001). PNI was positively correlated with total lymphocyte count (r = 0.707, p < 0.001) and with LMR (r = 0.480, p < 0.001), while it was negatively associated with neutrophil-to-lymphocyte ratio [NLR (r = −0.394, p < 0.001)] and with platelet-to-lymphocyte ratio [PLR (r = −0.410, p < 0.001)] [9]. Therefore, low PNI was found to be associated with poorer survival outcomes in patients treated with surgery and adjuvant CT for localized CRC.…”

Section: Colorectal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Nutritional Assessment in Gastrointestinal Tumors: News from the 2020 ASCO and ESMO World GI Meetings

Mascaretti

Evangelista

2020

Gastrointestinal Disorders

View full text Add to dashboard Cite

Nutritional risk screening and assessment of general nutritional status are of primary importance in the management of gastrointestinal cancers (GIC). Indeed, a major problem in these patients is the involuntary weight loss leading eventually to cachexia. With our review, we aimed at collecting the most recent advances in nutritional assessment of patients with GIC. All the abstracts presented both at the 2020 ASCO and ESMO World GI meetings were considered and a total number of 12 abstracts were selected, reporting colorectal, gastric, esophageal, and pancreatic cancer (PC) series. In some of the analyzed series, pathological conditions such as cachexia and sarcopenia had prognostic significance on clinical outcomes. One abstract reported the results of a phase I trial with the use of a novel interleukin-1-alpha antagonist, bermekimab. Its association with standard chemotherapy in advanced PC brought an improved patients’ performance during treatment. Insufficient attention is paid to the nutritional status of patients with GIC both at screening and during specific cancer treatment. The use of antropometric measurements, together with nutritional assessment tools, may facilitate the clinical evaluation of these patients. Large randomized trials are warranted in order to clarify the real impact of nutritional interventions on clinical outcomes.

show abstract

“…In particular, specific grading of the reported deficits is missing [27]. In the analyzed abstracts, both PNI [9,14] and PG-SGA found application [12,13].…”

Section: Discussionmentioning

confidence: 99%

Section: Colorectal Cancermentioning

confidence: 99%